Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Indee Labs

Indee Labs

Indee Labs focuses on the development of microfluidic vortex shedding for rapidly and efficiently transfecting human primary immune cells with negligible perturbation. The team is focused on developing its core technology for short turnaround chimeric antigen receptor T cell (CAR-T) development and manufacturing.

Indee Labs was founded in August 2015 with a "mission to democratize gene-modified cell therapies," such as chimeric antigen receptor T cells (CAR-T). The team is developing a novel transfection technology that can rapidly and efficiently deliver a variety of genetic material (e.g., DNA, RNA, protein, and/or various complexes) to human primary immune cells in seconds.

Microfluidic vortex shedding

The core technology, microfluidic vortex shedding (µVS), uses a microscopic fluid dynamics phenomenon based on vortex shedding to hydrodynamically porate the cell membrane, allowing for the deliberate introduction of genetic material to human primary immune cells. Vortex shedding is not a new phenomenon. It can be observed as water flows past boulders in rivers while also being seen as clouds drift over mountains.

µVS is not the only transfection technology; however, it is shown to be able to rapidly deliver a range of genetic material to human primary immune cells with high cell recovery, high cell viability, high efficiency, and high throughput. Furthermore, µVS results in negligible perturbation of immune cell proliferation, activation, exhaustion, phenotype, function, and transcriptome-wide gene expression. µVS is also induced with a 5 mm x 10 mm microfluidic device manufactured using industry-standard semiconductor processes. Cumulatively, this means µVS is an extremely scalable, gentle, and robust alternative to incumbent technologies, such as viral transduction and electroporation.


As of May 2018, Indee Labs had accumulated more than USD$6.1 million dollars in angel, venture, and non-dilutive capital.


In July 2017, Indee Labs closed USD$1.3M in accelerator and angel financing from SOSV, IndieBio, Jude Gomila, Shaun Maguire, Y Combinator and Jaffray Woodriff (executed by his family office, Felton Group, LLC) among others.


In May 2018, Indee Labs closed out a seed round resulting in USD$2.6M in angel and venture financing from Founders Fund, Main Sequence Ventures, Social+Capital also among others.

Non-dilutive Funding

Funding Agency

BioMedTech Horizons Precision Medicine

MTP Connect



Minimum Viable Product

Jobs for NSW



Phase I SBIR

National Institute for Allergy and Infectious Disease




February 1, 2018
Indee Labs presents at MF-9, the Ninth Microfluidics Consortium.
January 24, 2018
Indee Labs is featured by Main Sequence Ventures

January 8, 2018
Indee Labs is mentioned by the Australian Trade and Investment Com.
December 7, 2017
Indee Labs is selected for the Wilson Sonsini Goodrich & Rosati Healthcare Innovations Venture Investment Forum.
November 15, 2017
Indee Labs is featured by Eagar & Martin Patent & Trademark Attorneys.
October 4, 2017
Amy Twite presents a Lightning Talk at Synbiobeta.
July 3, 2017
Indee Labs closes $1.3M Angel Round.
May 24, 2017
Indee Labs selected to present at Australian-American Enabling Technologies Meeting.
March 20, 2017
Indee Labs launches at Y Combinator’s Winter 2017 Demo Day.

Funding Rounds



Further Resources


Intracellular delivery of mRNA to human primary T cells with microfluidic vortex shedding

Amy A. Twite, Katherine H.W.J. Lau, Moein N. Kashani, Craig Priest, Jorge Nieva, David Gottlieb, Ryan S. Pawell


Intracellular delivery of mRNA to human primary T cells with microfluidic vortex shedding

Justin A. Jarrell, Amy A. Twite, Katherine H. W. J. Lau, Moein N. Kashani, Adrian A. Lievano, Julyana Acevedo, Craig Priest, Jorge Nieva, David Gottlieb & Ryan S. Pawell

Nature Scientific Reports


Golden logo
By using this site, you agree to our Terms & Conditions.